Navigation Links
Data Show Dutasteride Reduces Prostate Cancer Diagnosis in Men With Increased Risk
Date:4/28/2009

REDUCE Trial data presented during American Urological Association Annual Meeting, April 27

CHICAGO, April 28 /PRNewswire-USNewswire/ -- Dutasteride (Avodart), a commonly prescribed drug to treat benign prostatic hyperplasia, has been shown to lower the risk of prostate cancer by 23 percent in men with an increased risk of the disease, according to results of an international clinical trial presented yesterday at the American Urological Association (AUA) Annual Meeting in Chicago. Data from the REDUCE Trial was presented to members during the plenary session, and lead investigator Gerald Andriole, MD, of Washington University School of Medicine in St. Louis, held a special session for interested media at 12:15 p.m. in the AUA Press Suite.

The REDUCE trial is the first to examine chemoprevention for prostate cancer in men at increased risk for the disease. The trial involved 8,200 men ages 50 - 75 who were randomly assigned to receive a placebo or a daily 0.5 mg dose of dutasteride. Men in the study had elevated PSA levels (2.5 - 10 ng/ml) indicating that they were at increased risk of prostate cancer. They had undergone biopsies that found no evidence of cancer within six months prior to enrolling in the trial. Therefore these men either did not have prostate cancer or possibly had microscopic tumors that were too small to be detected by the pre-study biopsy.

The investigators performed scheduled biopsies on the men two years after they enrolled in the study and again after four years. After two years, prostate cancer was found in 17.2 percent of the men who took a placebo, compared with 13.4 percent who took dutasteride. After four years, prostate cancer was diagnosed in another 11.8 percent of men who received a placebo and 9.1 percent who received dutasteride.

"In these men, the most likely explanation is that dutasteride worked by shrinking tumors and/or slowing their growth, thereby making them less likely to be detected by a biopsy," Dr. Andriole said. "This drug has the potential to offer many thousands of men a way to reduce their risk of being diagnosed with prostate cancer and, as a result, more men could avoid treatment for prostate cancer and the cost and unwanted side effects associated with treatment."

The investigators found that there was no greater risk for the men who did develop prostate cancer to have aggressive tumors. This outcome was closely watched because an earlier trial of a similar BPH drug - finasteride (Proscar) - produced controversial results with regard to the risk of more aggressive tumors in those men who developed prostate cancer while on finasteride. An initial analysis of the finasteride data suggested that there was an increased risk for men to have prostate cancer with higher Gleason scores but a later analysis suggested that there is probably no greater risk for these men to develop higher grade prostate cancer.

Over the course of the current study, 6.8 percent of men in the placebo group and 6.7 percent of men in the dutasteride group were found to have aggressive, high-grade tumors, defined as a Gleason score of 7 - 10.

"We are very encouraged by this finding," Dr. Andriole says. "Clearly, the data show dutasteride did not lead to more high-grade tumors, even though they would have been easier to detect in the dutasteride-treated men due to their smaller prostates."

The REDUCE (Reduction by Dutasteride of Prostate Cancer Events) trial was conducted at 250 sites in 42 countries around the world. The study was funded by GlaxoSmithKline. Dr. Andriole is chairman of the REDUCE steering committee and a consultant for the company.

For more information about this presentation, please contact AUA Communications Manager Wendy Waldsachs Isett at 410-977-4770.

About the American Urological Association: Founded in 1902 and headquartered near Baltimore, Maryland, the American Urological Association is the pre-eminent professional organization for urologists, with more than 16,000 members throughout the world. An educational nonprofit organization, the AUA pursues its mission of fostering the highest standards of urologic care by carrying out a wide variety of programs for members and their patients.

    Contact:
    Wendy Waldsachs Isett, AUA
    Cell: 410-977-4770

    AUA On-Site Press Suite
    312-528-8253


'/>"/>
SOURCE American Urological Association
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. New study: Pine bark reduces perimenopausal symptoms
2. Different method of evaluating the urinary tract system reduces radiation dose
3. Saline Reduces Mortality for Brain Injury Patients
4. New study: Pine bark extract reduces ADHD symptoms in children
5. Radiation therapy technique reduces length of prostate cancer treatment
6. Radiation therapy technique reduces length of prostate cancer treatment
7. MR spectroscopy identifies breast cancer, reduces biopsies
8. Body-mind meditation boosts performance, reduces stress
9. Parkinsons Institute research shows that nicotine reduces levodopa-induced dyskinesias
10. VIDEO from Medialink and EcoQuest: New Technology Reduces Exposure to MRSA Staph
11. Ranexa(R) Significantly Reduces Incidence of CV Death, MI or Recurrent Ischemia in MERLIN TIMI-36 Patients With Elevated BNP
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/18/2017)... Dallas, Texas (PRWEB) , ... February 17, 2017 , ... ... Arden Moore’s “Oh Behave” Show on the Pet Life Radio network. The episode, ... explores a number of topics including: what factors led to Park Cities Pet Sitter’s ...
(Date:2/17/2017)... CA (PRWEB) , ... February 17, 2017 , ... ... focus on foundational and sustainable systems change designed to further positively impact the ... “The Board of Trustees has long considered it our duty to seriously consider ...
(Date:2/17/2017)... ... February 17, 2017 , ... Corrective ... Warning Letter, **An FDAnews Webinar**, Feb. 23, 2017 — 1:30 p.m. – 3:00 ... corrective action (CA) and preventive action (PA)? , The methods share techniques and ...
(Date:2/17/2017)... ... February 17, 2017 , ... Pharmica Consulting attended CHI's ... facets of clinical trial planning and management. Pharmica discussed the importance of effective ... addition, attendees stopping by Pharmica’s booth were able to demo its cloud-based ...
(Date:2/17/2017)... ... 2017 , ... The Mason Pasquin Agency, a Virginia-based firm ... in and around the Hampton Roads metropolitan region, is joining the local nonprofit ... violence. , There are multiple categories of domestic violence – physical abuse is ...
Breaking Medicine News(10 mins):
(Date:2/16/2017)... DaVita Inc. (NYSE: DVA ) today ... 2016. Net income attributable to DaVita Inc. ... $158 million, or $0.80 per share and $880 million, or ... attributable to DaVita Inc. for the quarter and year ended ... $192 million, or $0.98 per share, and $789 million, or ...
(Date:2/16/2017)... -- Newly published research from the CVS Health (NYSE: ... private retailer can play in restricting access to tobacco ... in the American Journal of Public Health , ... all CVS Pharmacy stores reduced the number of cigarette ... impact on those who bought cigarettes exclusively at CVS ...
(Date:2/16/2017)... 16, 2017  Prescription pain medications provided by "physicians ... necessary for long-term opioid use to take hold," according ... edition of The New England Journal of ... more patients in acute pain than in almost any ... FACEP, president of the American College of Emergency Physicians. ...
Breaking Medicine Technology: